We are live on ! Find out more
RNTX icon

Rein Therapeutics

20 hedge funds and large institutions have $3.24M invested in Rein Therapeutics in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

148% more capital inflows, than outflows

Capital inflows: $162K | Capital outflows: $65.2K

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

25% more funds holding

Funds holding: 16 → 20 (+4)

1.28% less ownership

Funds ownership: 23.03% → 21.75% (-1.3%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
20
Holders Change
+4
Holders Change %
+25%
% of All Funds
0.29%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
7
Increased
4
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

RNTX Hedge Fund Activity: Q4 2023 in Review

20 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q4 2023, worth a combined $3.24M — up 104% from $1.59M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new RNTX positions and 2 closed out — a net gain of 5 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Gagnon Securities, opening a new position worth an estimated $74K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $30.4K sold.

  • 20 institutional investors held Rein Therapeutics (RNTX) as of Q4 2023, up from 16 in Q3 2023.
  • Funds reported $3.24M of Rein Therapeutics stock for Q4 2023, up 104% quarter-over-quarter.
  • 7 funds opened new Rein Therapeutics positions in Q4 2023 and 2 closed out, a net change of +5 holders.
  • The largest Rein Therapeutics buyer in Q4 2023 was Gagnon Securities, an estimated $74K added.
  • The largest Rein Therapeutics seller in Q4 2023 was Susquehanna International Group, an estimated $30.4K sold.

Based on aggregated 13F filings for Q4 2023.